Collectively, our data uncover a novel mechanism of trastuzumab resistance driven by circular RNA-encoded peptides, meanwhile provide a proof-of-concept demonstration for a potential strategy to resensitize trastuzumab-resistant HER2-positive breast cancer patients to trastuzumab. Here, ERBB2 is linked to breast carcinoma.